NASDAQ:OKUR OnKure Therapeutics Q3 2026 Earnings Date & Estimates $2.41 +0.11 (+4.78%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.41 0.00 (0.00%) As of 10/9/2026 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. OnKure Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call DateNovember 6, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from OnKure Therapeutics in Q3 2026OnKure Therapeutics is expected to post earnings of -$0.36 per share on revenue of $0.17 million. In the same quarter a year earlier OnKure Therapeutics reported -$1.09 per share. OnKure Therapeutics last reported on August 4, 2026, posting -$0.31 per share and beating the -$0.5350 consensus estimate. OnKure Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.36Expected Revenue$0.17 millionPrior-Year EPS-$1.09Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.31 (Beat by +$0.2250)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report OnKure Therapeutics Q3 2026 Earnings FAQ When does OnKure Therapeutics report Q3 2026 earnings? OnKure Therapeutics (NASDAQ:OKUR) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is OnKure Therapeutics' Q3 2026 earnings call? OnKure Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for OnKure Therapeutics? Analysts expect OnKure Therapeutics to post earnings of -$0.36 per share for Q3 2026. How much revenue is OnKure Therapeutics expected to report? The consensus revenue estimate for OnKure Therapeutics is $0.17 million for Q3 2026. OnKure Therapeutics Earnings HeadlinesOnkure Therapeutics Inc (OKUR)September 25, 2026 | investing.comOnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare ConferenceAugust 31, 2026 | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)OnKure Therapeutics Inc. - Ordinary Shares - Class AAugust 19, 2026 | money.usnews.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)August 6, 2026 | theglobeandmail.comOnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsAugust 4, 2026 | globenewswire.comSee More OnKure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email. Email Address About OnKure TherapeuticsOnKure Therapeutics (NASDAQ:OKUR) is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research is centered on small-molecule therapies intended to target biological pathways that contribute to tumor growth and immune suppression. OnKure’s lead investigational product is OKN4395, an orally administered EP2 receptor antagonist designed to help restore anti-tumor immune activity within the tumor microenvironment. The company has been evaluating OKN4395 in combination with pembrolizumab, an immune checkpoint inhibitor, for patients with advanced solid tumors. As an investigational therapy, OKN4395 has not been approved for commercial use. Based in Boulder, Colorado, OnKure serves the oncology research and clinical-development market through its drug discovery and clinical programs. The company’s activities are primarily focused on advancing targeted cancer treatments through clinical development and potential regulatory approval.View OnKure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
